Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
暂无分享,去创建一个
A. Giobbie-Hurder | S. Carter | D. Cahill | B. Nahed | P. Brastianos | A. Bardia | H. Shih | N. Lin | D. Juric | E. Lee | B. Overmoyer | E. Gerstner | D. Forst | J. Dietrich | Naema Nayyar | U. Chukwueke | C. Alvarez-Breckenridge | M. Strickland | K. Oh | I. Dagogo-Jack | P. Jones | Justine V. Cohen | A. Eichler | A. Kim | Michael D. White | Wendy Y. Chen | R. Sullivan | Nancy Wang | M. Mahar | J. Mora | J. Cohen | Deborah A Forst
[1] Brian L. Shaw,et al. Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases , 2021, Nature Communications.
[2] D. de Ruysscher,et al. Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. , 2019, European journal of cancer.
[3] M. J. van den Bent,et al. How we treat patients with leptomeningeal metastases , 2019, ESMO Open.
[4] A. Awada. Faculty Opinions recommendation of Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[5] M. Atkins,et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain , 2018, The New England journal of medicine.
[6] C. Bettegowda,et al. Current state of immunotherapy for glioblastoma , 2018, Nature Reviews Clinical Oncology.
[7] J. Wilmott,et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. , 2018, The Lancet. Oncology.
[8] A. Melcher,et al. Anti–PD-1/anti–CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking , 2018, Proceedings of the National Academy of Sciences.
[9] P. Brastianos,et al. Leptomeningeal metastasis from systemic cancer: Review and update on management , 2018, Cancer.
[10] L. Dirix,et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study , 2017, Breast Cancer Research and Treatment.
[11] A. Vortmeyer,et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. , 2016, The Lancet. Oncology.
[12] S. Loi,et al. Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis , 2016, Breast Cancer Research.
[13] S. Loi,et al. Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis , 2016, Breast Cancer Research.
[14] Naoya Hashimoto,et al. NIMG-56IMMUNOTHERAPY RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (iRANO): A REPORT OF THE RANO WORKING GROUP , 2015 .
[15] Naoya Hashimoto,et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. , 2015, The Lancet. Oncology.
[16] C. Villarreal-Garza,et al. Clinical Features and Prognostic Factors in Patients with Carcinomatous Meningitis Secondary to Breast Cancer , 2012, The breast journal.
[17] J. Wolchok,et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. , 2012, The Lancet. Oncology.
[18] M. Chamberlain. Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series , 2012, Journal of Neuro-Oncology.
[19] P. Beauchesne. Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. , 2010, The Lancet. Oncology.
[20] M. Chamberlain,et al. Leptomeningeal Metastasis , 2010, Seminars in neurology.
[21] J. Shih,et al. Cytologically proven meningeal carcinomatosis in patients with lung cancer: clinical observation of 34 cases. , 2008, Journal of the Formosan Medical Association = Taiwan yi zhi.
[22] M. Høyer,et al. [Meningeal carcinomatosis]. , 2005, Ugeskrift for laeger.
[23] B. Doebbeling,et al. Meningeal carcinomatosis from breast cancer: Spinal cord vs. brain involvement , 2005, Breast Cancer Research and Treatment.
[24] S. Grossman,et al. Leptomeningeal carcinomatosis. , 1999, Cancer treatment reviews.
[25] M. Chamberlain,et al. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. , 1997, Journal of neurosurgery.
[26] D. Ettinger,et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. P. Glass,et al. Leptomeningeal metastasis , 1993, Neurology.
[28] A. Hart,et al. Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma , 1983, Neurology.
[29] R. Makuch,et al. Carcinomatous Leptomeningitis in Small Cell Lung Cancer: A Clinicopathologic Review of the National Cancer Institute Experience , 1982, Medicine.
[30] J. Adams,et al. Diffuse involvement of the leptomeninges by tumour--a clinical and pathological study of 63 cases. , 1980, Postgraduate medical journal.
[31] A. J. Dale,et al. Meningeal carcinomatosis. Clinical manifestations. , 1974, Archives of neurology.